Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement
Sjoerd Rodenhuis(The Netherlands Cancer Institute), Emiel J. Rutgers(Oncode Institute), Otilia Dalesio(The Netherlands Cancer Institute), Jacques Borger(The Netherlands Cancer Institute), Elsken van der Wall(University Medical Center Utrecht), Jan H. Schornagel, Dick J. Richel(Amsterdam UMC Location University of Amsterdam), Johannes L. Peterse(The Netherlands Cancer Institute), Caro C.E. Koning(Amsterdam UMC Location University of Amsterdam), Joke W. Baars(The Netherlands Cancer Institute), Willem J. Nooijen(The Netherlands Cancer Institute), Roel Bakx(Dutch Cancer Society)
Cited by 243
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k